Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension

Cardiovascular Research

Volumn 87, Issue 3, 2010, Pages 569-577

  Bagnost, Teddy ^a   Ma, Ling ^a   Da Silva, Rafaela F ^b,c   Rezakhaniha, Rana ^b   Houdayer, Christophe ^d   Stergiopulos, Nikos ^b   André, Claire ^a   Guillaume, Yves ^a   Berthelot, Alain ^a   Demougeot, Céline ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b EPFL   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Arginase; Arteries; Endothelial function; Remodelling; Spontaneously hypertensive rat

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ARGINASE; ARGINASE 1; COLLAGEN; ENZYME INHIBITOR; N OMEGA HYDROXYNORARGININE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; ARGININE; CARDIOVASCULAR AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MEMBRANE PROTEIN; N(OMEGA)-HYDROXYNORARGININE; PTGS1 PROTEIN, RAT; PTGS2 PROTEIN, RAT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CONTROLLED STUDY; ENZYME INHIBITION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VASODILATATION; WISTAR KYOTO RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BLOOD PRESSURE; COMPLIANCE (PHYSICAL); DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENETICS; HEART DISEASES; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME; VASOCONSTRICTION;

ANIMALS; AORTA; ARGINASE; ARGININE; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; COLLAGEN; COMPLIANCE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FIBROSIS; HEART DISEASES; HYPERTENSION; MALE; MEMBRANE PROTEINS; MESENTERIC ARTERIES; MYOCARDIUM; NITRIC OXIDE SYNTHASE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 77954812507     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq081     Document Type: Article

References (44)

1. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Phys 1996;114:107-132.
2. v-hydroxy-L- arginine during high-output NO production. Am J Physiol 1996;271:H1988-H1998.
3. Ignarro LJ, Buga G, Wie LH, Bauer PM, Wu G, del Soldato P. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001;98:4202-4208.
4. Zhang C, Hein TW, Wang W, Miller MW, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric-oxide-mediated vaso-dilatory function. FASEB J 2001;15:1264-1266.
5. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 2005;25:971-978.
6. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008;102:923-932.
7. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 2008;31:134-139.
8. Masuda H. Significance of nitric oxide and its modulation mechanisms by endogenous nitric oxide synthase inhibitors and arginase in the micturition disorders and erectile dysfunction. Int J Urol 2008;15:128-134.
9. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003;108:2000-2006.
10. Lüscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens 1994;12:S106-S116.
11. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 2000;22:75-85.
12. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arterial endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2005;288:R1057-R1062.
13. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM et al. Upre-gulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004;44:1-9.
14. Demougeot C, Prigent-Tessier A, Bagnost T, André C, Guillaume Y, Bouhaddi M et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci 2007;80:1128-1134.
15. Holowatz LA, Kenney WL. Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol 2007;581: 863-872.
16. Bagnost T, Berthelot A, Bouhaddi M, Laurant P, André C, Guillaume Y et al. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 2008;26:1110-1118.
17. Redon J. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Curr Opin Nephrol Hypertens 2005; 14:448-452.
18. Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994;174:231-235.
19. Fonck E, Prod'hom G, Roy S, Augsburger L, Rüfenacht DA, Stergiopulos N. Effect of elastin degradation on carotid wall mechanics as assessed by a constituent-based bio-mechanical model. Am J Physiol Heart Circ Physiol 2007;292:H2754-H2763.
20. Fridez P, Makino A, Miyazaki H, Meister JJ, Hayashi K, Stergiopulos N. Short-term bio-mechanical adaptation of the rat carotid to acute hypertension: contribution of smooth muscle. Ann Biomed Eng 2001;29:26-34.
21. Aras-Lopéz R, Blanco-Rivero J, Xavier FE, Salaices M, Ferrer M, Balfagón G. Dexa-methasone decreases contraction to electrical field stimulation in mesenteric arteries from spontaneously hypertensive rats through decreases in thromboxane A2 release. J Pharmacol Exp Ther 2007;322:1129-1136.
22. Alvarez Y, Pérez-Girón JV, Hernanz R, Briones AM, Garć?a-Redondo A, Beltrán A et al. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther 2007;321:381-388.
23. Liu H, Ledingham JM, Mullaney I, Laverty R. Endothelial function in mesenteric resistance arteries from the genetically hypertensive rat. Clin Exp Pharmacol Physiol 2002;29: 405-411.
24. Endemann D, Touyz RM, Li JS, Deng LY, Schiffrin EL. Altered angiotensin II-induced small artery contraction during the development of hypertension in spontaneously hypertensive rats. Am J Hypertens 1999;12:716-723.
25. Girouard H, de Champlain J. Acute and chronic effects of free radicals on alpha1-adrenergic-induced vasoconstriction in mesenteric beds of spontaneously hypertensive rats. J Hypertens 2005;23:807-814.
26. Montagnani M, Potenza MA, Rinaldi R, Mansi G, Nacci C, Serio M et al. Functional characterization of endothelin receptors in hypertensive resistance vessels. J Hypertens 1999;17:45-52.
27. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:906-911.
28. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglan-din biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005;57: 217-252.
29. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001;38:581-587.
30. Yokoyama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, Ferrario CM. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005;18:922-929.
31. Bravo R, Somoza B, Ruiz-Gayo M, González C, Ruilope LM, Fernández-Alfonso MS. Differential effect of chronic antihypertensive treatment on vascular smooth muscle cell phenotype in spontaneously hypertensive rats. Hypertension 2001;37:E4-E10.
32. Ibrahim J, Hughes AD, Schachter M, Sever PS. Enhanced tissue polyamine content in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1996;23:410-414.
33. Lipke DW, Newman PS, Tofiq S, Guo H, Arcot SS, Aziz SM et al. Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension. Clin Exp Hypertens 1997;19:269-295.
34. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001;280:E75-E82.
35. Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM et al. Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol 2009;29:488-494.
36. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005;45:432-437.
37. Lüscher TF, Dohi Y, Tschudi M. Endothelium-dependent regulation of resistances arteries: alterations with aging and hypertension. J Cardiovasc Pharmacol 1992;19: S34-S42.
38. Wang X, Keith JC Jr, Struthers AD, Feuerstein GZ. Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther 2008;26:214-223.
39. Wallace SM, Yasmin, McEniery CM, Mäki-Petäjä KM, Booth AD, Cockcroft JR et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endo-thelial dysfunction. Hypertension 2007;50:228-233.
40. Marano G, Grigioni M, Palazzesi S, Ferrari AU. Endothelin and mechanical properties of the carotid artery in Wistar-Kyoto and spontaneously hypertensive rats. Cardio-vasc Res 1999;41:701-707.
41. Safar M, Chamiot-Clerc P, Dagher G, Renaud JF. Pulse pressure, endothelium function, and arterial stiffness in spontaneously hypertensive rats. Hypertension 2001;38: 1416-1421.
42. Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 2008;34:957-963.
43. Meroufel D, Dumont J, Médiène-Benchekor S, Benhammamouch S, Ducimetière P, Cottel D et al. Characterization of arginase 1 gene polymorphisms in the Algerian population and association with blood pressure. Clin Biochem 2009;42:1178-1182.
44. Dumont J, Zureik M, Cottel D, Montaye M, Ducimetière P, Amouyel P et al. Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. J Med Genet 2007;44:526-531.